Zobrazeno 1 - 10
of 38
pro vyhledávání: '"Stephen Falk"'
Autor:
Robin M. Rudd, Richard Jones, Alex Edwards, Siow Ming Lee, Matthew Hatton, Allan Hackshaw, Geraldine Skailes, Elizabeth Toy, Yenting Ngai, Sunil Upadhyay, Penella J. Woll, Stephen Falk, Rohit Lal, Conrad R. Lewanski
Publikováno v:
European Journal of Cancer
Purpose We previously demonstrated that the median survival of patients with poor prognosis non–small cell lung cancer (NSCLC) considered unfit for first-line platinum chemotherapy was
Highlights • 83% advanced NSCLC patients unfit for chemo
Highlights • 83% advanced NSCLC patients unfit for chemo
Autor:
Mark R. Middleton, P S Virdee, Leena Elhussein, Martin Eatock, M Goff, Sharon Love, Anne Thomas, Stephen Falk, Joanna Moschandreas, Richard C. Turkington, D. Alan Anthoney, L Collins, Simon Lord
Publikováno v:
Thomas, A, Virdee, P S, Eatock, M, Lord, S R, Falk, S, Anthoney, D A, Turkington, R C, Goff, M, Elhussein, L, Collins, L, Love, S, Moschandreas, J & Middleton, M R 2020, ' Dual Erb B Inhibition in Oesophago-gastric Cancer (DEBIOC): A phase I dose escalating safety study and randomised dose expansion of AZD8931 in combination with oxaliplatin and capecitabine chemotherapy in patients with oesophagogastric adenocarcinoma ', European Journal of Cancer, vol. 124, pp. 131-141 . https://doi.org/10.1016/j.ejca.2019.10.010
European Journal of Cancer
European Journal of Cancer
Background AZD8931 has equipotent activity against epidermal growth factor receptor, erbB2, and erbB3. Primary objectives were to determine the recommended phase II dose (RP2D) of AZD8931 + chemotherapy, and subsequently assess safety/preliminary cli
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d3f3f4d7b04b1b1073ec0ebfa84b2946
https://pure.qub.ac.uk/en/publications/1ea96e9e-4701-4ab7-aa91-f416c1e2f897
https://pure.qub.ac.uk/en/publications/1ea96e9e-4701-4ab7-aa91-f416c1e2f897
Autor:
Stephen Falk, Susan J Dutton, Wasat Mansoor, David A J Stevenson, Caroline Clark, Russell D. Petty, Aileen Osborne, Asa Dahle-Smith, Angel Garcia-Alonso, Mark Harrison, Joyce Thompson, Graeme I. Murray, Ian Chau, Irene Chong, Jonathan Wadsley, Corran Roberts, Doreen Massie, Zosia Miedzybrodzka, Anirban Chatterjee, Sean Elyan, David Walter Fyfe, David Ferry
Publikováno v:
Journal of Clinical Oncology. 35:2279-2287
Purpose The Cancer Esophagus Gefitinib trial demonstrated improved progression-free survival with the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor gefitinib relative to placebo in patients with advanced esophageal cancer who had
Autor:
Richard, Adams, Ewan, Brown, Louise, Brown, Rachel, Butler, Stephen, Falk, David, Fisher, Richard, Kaplan, Phil, Quirke, Susan, Richman, Leslie, Samuel, Jenny, Seligmann, Matt, Seymour, Kai Keen, Shiu, Harpreet, Wasan, Richard, Wilson, Tim, Maughan
Publikováno v:
The lancet. Gastroenterologyhepatology. 3(3)
A substantial change in trial methodology for solid tumours has taken place, in response to increased understanding of cancer biology. FOCUS4 is a phase 2-3 trial programme testing targeted agents in patients with advanced colorectal cancer in molecu
Autor:
M Peterson, Juan W. Valle, Myrddin Rees, Louise Stanton, David Cunningham, Tamas Hickish, Timothy Iveson, Joanne Hornbuckle, Elizabeth Dixon, Tim Maughan, O. J. Garden, John Bridgewater, Rachel Butler, Derek A. O'Reilly, John N. Primrose, Louisa Little, Ajith K. Siriwardena, Stephen Falk, S Pugh, Megan Bowers, M Finch-Jones
Publikováno v:
The Lancet Oncology. 15:601-611
Summary Background Surgery for colorectal liver metastases results in an overall survival of about 40% at 5 years. Progression-free survival is increased with the addition of oxaliplatin and fluorouracil chemotherapy. The addition of cetuximab to the
Autor:
Ruby Ray, Simon Gollins, J. Ian Geh, Jane M Blazeby, Thomas Crosby, John Staffurth, Gareth Griffiths, Stephen Falk, Chris Nicholas Hurt, Somnath Mukherjee, Tim Maughan, John Bridgewater, David Cunningham, Rajarshi Roy, Nadim Bashir
Publikováno v:
The Lancet Oncology. 14:627-637
BACKGROUND: Definitive chemoradiotherapy (CRT) is an alternative to surgery for the curative treatment of oesophageal carcinoma. The SCOPE1 trial aimed to investigate the addition of cetuximab to cisplatin and fluoropyrimidine-based definitive CRT in
Autor:
Tom, Waddell, Ian, Chau, David, Cunningham, David, Gonzalez, Alicia Frances Clare, Okines, Alicia, Frances, Clare, Okines, Andrew, Wotherspoon, Claire, Saffery, Gary, Middleton, Jonathan, Wadsley, David, Ferry, Wasat, Mansoor, Tom, Crosby, Fareeda, Coxon, David, Smith, Justin, Waters, Timothy, Iveson, Stephen, Falk, Sarah, Slater, Clare, Peckitt, Yolanda, Barbachano
Publikováno v:
BASE-Bielefeld Academic Search Engine
The Lancet Oncology
The Lancet Oncology
Summary Background EGFR overexpression occurs in 27–55% of oesophagogastric adenocarcinomas, and correlates with poor prognosis. We aimed to assess addition of the anti-EGFR antibody panitumumab to epirubicin, oxaliplatin, and capecitabine (EOC) in
Autor:
C. J. Vickery, M. J. Lamparelli, R. Gupta, G. Maskell, A. C. Bateman, M. L. Hughes, Michael Braun, D. A. Agbamu, H. O'Neill, J. H. Scholefield, W. Faux, A. S. Myint, C. Macklin, H. J. Pearson, P. Richman, Geraint T. Williams, S. Sukumar, A. Kawesha, J. Robinson, Dion Morton, Caroline Finlayson, M. Saeed, A. Anathhanam, D. M. Melville, J. Whalley, Rizvana Ahmad, V. Howarth, E. Favill, Jacob G. Scott, M. Scott, D. Eason, S. M. Ahmad, Rajarshi Roy, M. Gupta, F. Lofts, N. Beharry, N. Lees, M. Charig, A. Buxton, Fiona Campbell, K. G. Walker, M. Train, P. Nichols, J. Mathew, G. Stenhouse, J. Orrell, P. Burn, D. Peake, S. P. Lake, D. Ilsley, A. J. Watson, A Mayer, A C Wotherspoon, David J. Smith, A. K. Thompson, J. Gutmann, W. K. Dunn, J. Huang, Tracy E Roberts, L. Meleagros, D. Cowlishaw, Angela E Taylor, P. Chandran, C. Bronder, B. Fozard, Jurjees Hasan, S. J. Needham, Rob Glynne-Jones, Jonathan Wadsley, F. Adab, J. Ostrowski, Andrew Bateman, I. T. Saeed, David Cunningham, E. Loveday, David Ferry, A. Hartley, K. Sleigh, A. Page, I. C. Ilesley, P. Cohen, D. Whillis, Phillipe Taniere, Paul J. Finan, S. Pritchard, S. Lee, A. Zaitoun, J. A. Rees, G. Langman, G. Howarth, D. Pai, D. Blunt, R. Osborne, W. Atkinson, D. Barber, O. A. Ogunbiyi, J. Harrison, H. Burnett, V. Sundaresan, S. Hayes, J. Livingstone, Simon Gollins, F. Daniel, G. Kurien, C. Holland, I. Britton, A. Sherif, Clifton D. Fuller, D. Shareef, Matthew T. Seymour, J. McCutcheon, C. Phelan, Charles Lowdell, R. M. Blaquiere, J. Alexander, A. Hamid, Sherif Raouf, A. Baxter, Tamas Hickish, Joanne Hornbuckle, A. Pallan, J. R.G. Bell, Graham Branagan, D. Tolan, A. Moss, J. Hampton, C. W. Hendrickse, D. Furniss, T. Burdge, Carolyn S. Hall, J. Watkins, C. Barlow, J. Hartley, P. Rooney, B. Pravee, Anne Pullyblank, C. Corr, A. Chiphang, J. Walther, Paris P. Tekkis, M. J. Dworkin, D. Eaton, R. Hagger, J. Mikel, A. Coup, M. Peters, S. Muzaffar, Sujal R. Desai, D. Tarver, C. Ramsey, Sarah Smith, J. Geraghty, N. Mapstone, Corran Roberts, John Bridgewater, S. Amin, P. Dawson, Vanessa Potter, C. J. Walsh, M. Pitt, N. Woodcock, S. Ramesh, Charlotte Rees, Nigel Scott, N. Steven, A. Maw, D. P. O'Leary, David Farrugia, S. Cook, D. Tsang, M. Callaway, P. Taylor, Andrew J. Hall, S. R. Muthuramalingam, S. A.M. Mangalika, N. Cruickshank, U. Raja, M. Dobson, C. Bale, R. W. Talbot, M. Qaiyum, M. Crabtree, Stephen H D Jackson, J. Hyde, S. Snape, Richard J. Ellis, R. Borgstein, A. Higginson, M. Thyveetil, Michael Thomas, A. Lowe, W. Partridge, Gina Brown, A. W. MacDonald, O. Lalude, M. Clwyd, Brendan J. Moran, G. T. Smith, Samir Mehta, B. T. Ismail, R. Donovan, P. Kitsanta, E. Kweka, N. Scot, K. Hopkins, N. Rooney, A. L. Desai, S. Jain, N. Wong, T. Iveson, Rubin Soomal, R. D. Taraporewalla, A. Clarke, J. Brittenden, S. Dundas, Marcia Hall, J. Denson, N. Day, Simon Aird Grumett, R. Church, M. Zeiderman, M. Steward, Daniel Swinson, S. Susnerwala, Stephen Falk, A. Malhotra, D. White, N. Pranesh, J. Haselden, James Hill, D. Scullion
Publikováno v:
The Lancet Oncology. 13:1152-1160
Background Preoperative (neoadjuvant) chemotherapy and radiotherapy are more effective than similar postoperative treatment for oesophageal, gastric, and rectal cancers, perhaps because of more effective micrometastasis eradication and reduced risk o
Autor:
Jakob R. Izbicki, Gary Middleton, Alan Anthoney, Paula Ghaneh, Harpreet Wasan, Kinnari Patel, David Cunningham, Olusola Olusesan Faluyi, Rubin Soomal, Thilo Hackert, John P. Neoptolemos, Christopher Halloran, Derek A. O'Reilly, Alec McDonald, Jonathan Wadsley, Yuk Ting Ma, Eftychia E. Psarelli, David Sherriff, Pascal Hammel, Markus W. Büchler, David Borg, Bengt Glimelius, Juan W. Valle, Roopinder Gillmore, Sharmila Sothi, Pehr Lind, Daniel H. Palmer, Tom Crosby, Tim Meyer, Richard J. Jackson, Paul Ross, Suzanne Darby, Stephen Falk, Sebastian Cummins
Publikováno v:
Lancet
Lancet (London, England)
European Study Group for Pancreatic Cancer 2017, ' Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trial. ', The Lancet, vol. 389, no. 10073, pp. 1011-1024 . https://doi.org/10.1016/S0140-6736(16)32409-6
Lancet (London, England)
European Study Group for Pancreatic Cancer 2017, ' Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trial. ', The Lancet, vol. 389, no. 10073, pp. 1011-1024 . https://doi.org/10.1016/S0140-6736(16)32409-6
Summary Background The ESPAC-3 trial showed that adjuvant gemcitabine is the standard of care based on similar survival to and less toxicity than adjuvant 5-fluorouracil/folinic acid in patients with resected pancreatic cancer. Other clinical trials
Autor:
Stephen Falk, Timothy Iveson, Juan W. Valle, Tim Maughan, John Bridgewater, S Pugh, Charlotte Rees, Tamas Hickish, Joanne Hornbuckle, Louise Stanton, Elizabeth Dixon, Margaret Finch-Jones, O. James Garden, Megan Bowers, John N. Primrose, Andrea Corkhill, Mike Radford, Derek A. O'Reilly, Tom Maishman, Ajith K. Siriwardena, David Cunningham, Alexandre Ball, Myrddin Rees
Publikováno v:
Pugh, S, Bowers, M, Ball, A, Falk, S, Finch-Jones, M, Valle, J, O’Reilly, D, Siriwardena, A, Hornbuckle, J, Rees, M, Rees, C, Iveson, T, Hickish, T, Maishman, T, Stanton, L, Dixon, E, Corkhill, A, Radford, M, Garden, O J, Cunningham, D, Maughan, T, Bridgewater, J & Primrose, J 2016, ' Patterns of progression, treatment of progressive disease and post-progression survival in the New EPOC Study ', British Journal of Cancer . https://doi.org/10.1038/bjc.2016.208
British Journal of Cancer
British Journal of Cancer
BackgroundThe addition of cetuximab to perioperative chemotherapy for operable colorectal liver metastases resulted in a shorter progression free survival. Details of disease progression are described to further inform the primary study outcome.Metho
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0cc4ffe90abd5689e79cc9239df9a363
https://hdl.handle.net/20.500.11820/591d165d-1475-4cab-b330-21d5b9b31636
https://hdl.handle.net/20.500.11820/591d165d-1475-4cab-b330-21d5b9b31636